Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epothilone Clear all
Completed Phase 2 Interventional

EPO906 Therapy in Patients With Advanced Kidney Cancer

NCT00035243
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

NCT00420615
View directory record Official record
Conditions
Solid Tumors
Interventions
Patupilone and Omeprazole, Patupilone + Midalzolam
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 4:50 AM EDT
Active, not recruiting Phase 1 Interventional

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01375829
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Ixabepilone, Pharmacological Study, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00022477
View directory record Official record
Conditions
Colorectal Cancer
Interventions
BMS-247550
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

NCT00325351
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sagopilone (ZK 219477) + carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 20, 2026, 4:50 AM EDT
Terminated Phase 1 Interventional

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

NCT00468260
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Stage IV Melanoma

NCT00036764
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ixabepilone, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

NCT00058084
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ixabepilone, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

NCT00426582
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Norwalk, Connecticut • Rockville, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

NCT01097642
View directory record Official record
Conditions
Breast Cancer
Interventions
Cetuximab, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

NCT00219297
View directory record Official record
Conditions
Brain Metastasis, Non-small Cell Lung Cancer
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
12
States / cities
Sacramento, California • Boston, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 20, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Ixabepilone to Treat Cervical Cancer

NCT00924066
View directory record Official record
Conditions
Cervical Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Carcinoma, Non-SquamousType
Interventions
Ixempra (Ixabepilone (BMS-247550) )
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

NCT00426140
View directory record Official record
Conditions
Advanced Malignancies, Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

NCT00421044
View directory record Official record
Conditions
Advanced Malignancies, Tumors
Interventions
Patupilone/EPO906
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
La Jolla, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
ixabepilone, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Farmington, Connecticut • Albany, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

NCT00448396
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

NCT00262990
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
EPO906 (Patupilone), doxorubicin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Flagstaff, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

NCT00496379
View directory record Official record
Conditions
Breast Cancer, CNS Disease
Interventions
ZK219477
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

NCT00017056
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00016393
View directory record Official record
Conditions
Prostate Cancer
Interventions
ixabepilone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
28
States / cities
Los Angeles, California • Sacramento, California • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis, Nab-paclitaxel, Paclitaxel, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
703
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

NCT00023946
View directory record Official record
Conditions
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
ixabepilone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

NCT00350051
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sagopilone (ZK 219477) + prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Fountain Valley, California • Sarasota, Florida • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 20, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors

NCT00030173
View directory record Official record
Conditions
Neoplasms
Interventions
Epothilone D (KOS-862)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Oct 20, 2026, 4:50 AM EDT